Mineralys Total Liab from 2010 to 2025
| MLYS Stock | 13.53 0.32 2.42% |
Total Liabilities | First Reported 2010-12-31 | Previous Quarter 14.6 M | Current Value 13.9 M | Quarterly Volatility 40.2 M |
Check Mineralys Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mineralys Therapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 15.3 M, Depreciation And Amortization of 143.6 K or Interest Expense of 2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.28. Mineralys financial statements analysis is a perfect complement when working with Mineralys Therapeutics, Valuation or Volatility modules.
Mineralys | Total Liab | Build AI portfolio with Mineralys Stock |
Latest Mineralys Therapeutics,'s Total Liab Growth Pattern
Below is the plot of the Total Liab of Mineralys Therapeutics, Common over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Mineralys Therapeutics,'s Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mineralys Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
Mineralys Total Liab Regression Statistics
| Arithmetic Mean | 18,482,231 | |
| Geometric Mean | 8,475,943 | |
| Coefficient Of Variation | 217.72 | |
| Mean Deviation | 20,474,567 | |
| Median | 5,083,000 | |
| Standard Deviation | 40,239,822 | |
| Sample Variance | 1619.2T | |
| Range | 161.6M | |
| R-Value | 0.34 | |
| Mean Square Error | 1530.3T | |
| R-Squared | 0.12 | |
| Significance | 0.19 | |
| Slope | 2,902,338 | |
| Total Sum of Squares | 24288.6T |
Mineralys Total Liab History
About Mineralys Therapeutics, Financial Statements
Mineralys Therapeutics, shareholders use historical fundamental indicators, such as Total Liab, to determine how well the company is positioned to perform in the future. Although Mineralys Therapeutics, investors may analyze each financial statement separately, they are all interrelated. The changes in Mineralys Therapeutics,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on Mineralys Therapeutics,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 14.6 M | 13.9 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.